MX370662B - Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. - Google Patents
Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer.Info
- Publication number
- MX370662B MX370662B MX2015011752A MX2015011752A MX370662B MX 370662 B MX370662 B MX 370662B MX 2015011752 A MX2015011752 A MX 2015011752A MX 2015011752 A MX2015011752 A MX 2015011752A MX 370662 B MX370662 B MX 370662B
- Authority
- MX
- Mexico
- Prior art keywords
- lung cancer
- methods
- treating lung
- nsclc
- carboplatin
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title 1
- 201000005202 lung cancer Diseases 0.000 title 1
- 208000020816 lung neoplasm Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 190000008236 carboplatin Chemical compound 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778299P | 2013-03-12 | 2013-03-12 | |
| PCT/US2014/022341 WO2014159171A1 (en) | 2013-03-12 | 2014-03-10 | Methods of treating lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011752A MX2015011752A (es) | 2015-12-07 |
| MX370662B true MX370662B (es) | 2019-12-19 |
Family
ID=51625117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011752A MX370662B (es) | 2013-03-12 | 2014-03-10 | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10744110B2 (enExample) |
| EP (2) | EP3698784A1 (enExample) |
| JP (3) | JP6349381B2 (enExample) |
| KR (1) | KR102191311B1 (enExample) |
| CN (2) | CN105228612A (enExample) |
| CA (1) | CA2903454A1 (enExample) |
| ES (1) | ES2804323T3 (enExample) |
| IL (1) | IL240935B (enExample) |
| MX (1) | MX370662B (enExample) |
| NZ (1) | NZ630392A (enExample) |
| WO (1) | WO2014159171A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN101605535A (zh) | 2006-12-14 | 2009-12-16 | 阿布拉科斯生物科学有限公司 | 用包含紫杉烷的纳米颗粒基于激素受体状态治疗乳腺癌 |
| LT2419732T (lt) | 2009-04-15 | 2020-03-10 | Abraxis Bioscience, Llc | Prionų neturinčios nanodalelių kompozicijos ir būdai |
| EP2552439B1 (en) | 2010-03-29 | 2022-07-20 | Abraxis BioScience, LLC | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| WO2011123395A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
| PH12012502380B1 (en) | 2010-06-04 | 2019-08-23 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| EP2701731B1 (en) | 2011-04-28 | 2020-07-29 | Abraxis BioScience, LLC | Intravascular delivery of nanoparticle compositions and uses thereof |
| MX374915B (es) | 2011-12-14 | 2025-03-06 | Abraxis Bioscience Llc | Uso de excipientes polimericos para liofilizacion o congelacion de particulas. |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| MX381140B (es) | 2015-06-29 | 2025-03-12 | Abraxis Bioscience Llc | Métodos para tratar tumores de células epitelioides. |
| JP6958161B2 (ja) * | 2017-09-20 | 2021-11-02 | コニカミノルタ株式会社 | プリンタ、スキャナプロファイル補正プログラム及びスキャナプロファイル補正方法 |
| SG11202009145PA (en) | 2018-03-20 | 2020-10-29 | Abraxis Bioscience Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| WO2020151727A1 (zh) * | 2019-01-23 | 2020-07-30 | 锐创生物医药(香港)有限公司 | 药物复合物及其制备方法和用途 |
| AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| KR20230170695A (ko) * | 2021-04-12 | 2023-12-19 | 랜턴 파마 인코포레이티드 | 폐암 및 비-소세포 폐암의 치료 방법 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| NZ262679A (en) | 1993-02-22 | 1997-08-22 | Vivorx Pharmaceuticals Inc | Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| KR100904931B1 (ko) * | 1997-06-27 | 2009-06-29 | 아브락시스 바이오사이언스, 엘엘씨 | 나노 입자 및 그의 제조 방법 |
| EP1171117A4 (en) | 1999-04-22 | 2002-08-07 | American Bioscience Inc | LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS |
| WO2000071079A2 (en) | 1999-05-21 | 2000-11-30 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| JP2005503398A (ja) * | 2001-09-13 | 2005-02-03 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | 化学塞栓用のパクリタキセルの混合組成物、その油中水型エマルジョン処方物及び製造方法 |
| ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| CN100479807C (zh) * | 2002-08-15 | 2009-04-22 | 刘云清 | 药物输送系统——固体纳米药物的制备方法 |
| KR20140027554A (ko) | 2002-12-09 | 2014-03-06 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR20190062506A (ko) | 2005-02-18 | 2019-06-05 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| NZ592132A (en) | 2005-08-31 | 2012-12-21 | Abraxis Bioscience Llc | Composition comprising nanoparticles of docitaxel and a citrate |
| RU2433818C2 (ru) | 2005-08-31 | 2011-11-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества |
| US8143236B2 (en) | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| JP2010502603A (ja) | 2006-08-31 | 2010-01-28 | アブラクシス バイオサイエンス， エルエルシー | 血管形成を阻害し、血管形成関連疾患を処置する方法 |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| CN101605535A (zh) | 2006-12-14 | 2009-12-16 | 阿布拉科斯生物科学有限公司 | 用包含紫杉烷的纳米颗粒基于激素受体状态治疗乳腺癌 |
| PT2481409T (pt) | 2007-03-07 | 2018-10-18 | Abraxis Bioscience Llc | Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno |
| EP3326630A3 (en) | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| WO2008150532A1 (en) | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| AU2009234127B2 (en) | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| JP2011517683A (ja) | 2008-04-10 | 2011-06-16 | アブラクシス バイオサイエンス， エルエルシー | 疎水性タキサン誘導体の組成物およびその使用 |
| ES2668837T3 (es) | 2008-12-11 | 2018-05-22 | Abraxis Bioscience, Llc | Terapia de combinación que incluye un taxano y un agente terapéutico adicional |
| KR101739598B1 (ko) | 2009-03-13 | 2017-06-08 | 아브락시스 바이오사이언스, 엘엘씨 | 티오콜키신 유도체와의 조합 요법 |
| EP2416650B1 (en) | 2009-04-10 | 2020-02-26 | Abraxis BioScience, LLC | Nanoparticle formulations and uses therof |
| LT2419732T (lt) | 2009-04-15 | 2020-03-10 | Abraxis Bioscience, Llc | Prionų neturinčios nanodalelių kompozicijos ir būdai |
| ES2577024T3 (es) | 2009-08-25 | 2016-07-12 | Abraxis Bioscience, Llc | Terapia combinada con composiciones de nanopartículas de taxano e inhibidores de Hedgehog |
| JP2013511549A (ja) | 2009-11-20 | 2013-04-04 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | ヘッジホッグ関連癌の治療のための方法及び組成物 |
| US9370494B2 (en) | 2010-03-26 | 2016-06-21 | Abraxis Bioscience, Llc | Methods for treating hepatocellular carcinoma |
| WO2011123395A1 (en) * | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
| EP2552439B1 (en) | 2010-03-29 | 2022-07-20 | Abraxis BioScience, LLC | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| RU2621640C2 (ru) | 2010-06-02 | 2017-06-06 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| PH12012502380B1 (en) | 2010-06-04 | 2019-08-23 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| EP3056201A1 (en) | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
| EP2701731B1 (en) | 2011-04-28 | 2020-07-29 | Abraxis BioScience, LLC | Intravascular delivery of nanoparticle compositions and uses thereof |
| MX374915B (es) | 2011-12-14 | 2025-03-06 | Abraxis Bioscience Llc | Uso de excipientes polimericos para liofilizacion o congelacion de particulas. |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| BR112015019064A8 (pt) | 2013-02-11 | 2019-11-12 | Abraxis Bioscience Llc | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| CA2903470A1 (en) | 2013-03-13 | 2014-09-18 | Abraxis Bioscience, Llc | Methods of treatment of pediatric solid tumor |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| US20170202782A1 (en) | 2014-04-06 | 2017-07-20 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| WO2016141365A1 (en) | 2015-03-05 | 2016-09-09 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
| CA2990705A1 (en) | 2015-06-29 | 2017-01-05 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| CA2990703C (en) | 2015-06-29 | 2024-04-30 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
| CN107921006A (zh) | 2015-06-29 | 2018-04-17 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法 |
| MX381140B (es) | 2015-06-29 | 2025-03-12 | Abraxis Bioscience Llc | Métodos para tratar tumores de células epitelioides. |
| US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
| US20180374583A1 (en) | 2017-05-16 | 2018-12-27 | Abraxis Bioscience, Llc | Nomogram and survival predictions for pancreatic cancer |
-
2014
- 2014-03-10 EP EP20167533.7A patent/EP3698784A1/en not_active Withdrawn
- 2014-03-10 CN CN201480027000.9A patent/CN105228612A/zh active Pending
- 2014-03-10 MX MX2015011752A patent/MX370662B/es active IP Right Grant
- 2014-03-10 ES ES14776420T patent/ES2804323T3/es active Active
- 2014-03-10 JP JP2016500945A patent/JP6349381B2/ja active Active
- 2014-03-10 CA CA2903454A patent/CA2903454A1/en not_active Abandoned
- 2014-03-10 US US14/772,335 patent/US10744110B2/en active Active
- 2014-03-10 NZ NZ630392A patent/NZ630392A/en unknown
- 2014-03-10 CN CN201910705763.9A patent/CN110279864A/zh active Pending
- 2014-03-10 KR KR1020157027993A patent/KR102191311B1/ko active Active
- 2014-03-10 WO PCT/US2014/022341 patent/WO2014159171A1/en not_active Ceased
- 2014-03-10 EP EP14776420.3A patent/EP2968254B1/en not_active Revoked
-
2015
- 2015-08-31 IL IL240935A patent/IL240935B/en active IP Right Grant
-
2018
- 2018-01-18 JP JP2018006177A patent/JP2018080198A/ja active Pending
-
2019
- 2019-09-11 JP JP2019165337A patent/JP2019206593A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ630392A (en) | 2016-10-28 |
| US10744110B2 (en) | 2020-08-18 |
| JP6349381B2 (ja) | 2018-06-27 |
| ES2804323T3 (es) | 2021-02-05 |
| WO2014159171A1 (en) | 2014-10-02 |
| CN105228612A (zh) | 2016-01-06 |
| JP2016512506A (ja) | 2016-04-28 |
| IL240935B (en) | 2018-12-31 |
| CN110279864A (zh) | 2019-09-27 |
| EP2968254A1 (en) | 2016-01-20 |
| JP2019206593A (ja) | 2019-12-05 |
| US20160015681A1 (en) | 2016-01-21 |
| JP2018080198A (ja) | 2018-05-24 |
| CA2903454A1 (en) | 2014-10-02 |
| KR102191311B1 (ko) | 2020-12-15 |
| MX2015011752A (es) | 2015-12-07 |
| EP2968254A4 (en) | 2017-03-15 |
| EP2968254B1 (en) | 2020-04-22 |
| IL240935A0 (en) | 2015-11-30 |
| KR20150126038A (ko) | 2015-11-10 |
| EP3698784A1 (en) | 2020-08-26 |
| HK1220110A1 (en) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX370662B (es) | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. | |
| MX364637B (es) | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. | |
| MX2015008889A (es) | Metodo para tratar cancer con base en el estado de la mutacion k-ras. | |
| MY188911A (en) | Methods of treating bladder cancer | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
| AU2016262079A8 (en) | Combination of analogs or derivatives of dianhydrogalactitol with platinum-containing antineoplastic agents to treat cancer | |
| MY184628A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| MX378934B (es) | Composición de nanopartículas para usarse en el tratamiento de cáncer de vejiga | |
| MX2017007321A (es) | Terapias de combinacion. | |
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| GEP20217211B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| MX2018011992A (es) | Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos. | |
| HK1216853A1 (zh) | 治療胰腺癌的方法 | |
| MX2021002455A (es) | Metodos para tratar tumores de celulas epitelioides. | |
| MX366623B (es) | 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas. | |
| HK1220155A1 (zh) | 治疗癌症的方法 | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| BR112015026292A2 (pt) | tratamento de câncer com dihidropirazino-pirazinas | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
| BR112019004906A2 (pt) | combinação incluindo abx196 para o tratamento de câncer | |
| MX356102B (es) | Compuestos y métodos para tratar leucemia. | |
| MX2017014463A (es) | Cabazitaxel y su uso para tratar cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |